Morphine, Buprenorphine, and Other Drugs Market By Emerging Trends, Revenue and Competitive Landscape: Purdue Pharma, Sun Pharmaceuticals, Pfizer Inc

Market Overview:

Morphine, buprenorphine and other drugs are widely used opioid drugs for chronic pain management. Morphine represents an effective option for long-term management of terminal cancer pain. Buprenorphine is commonly used to treat acute and chronic pain as well as opioid dependence.

Market Dynamics:

Increased prescription of opioid drugs like morphine, buprenorphine for chronic pain management conditions such as cancer pain, arthritis pain etc. is estimated to drive the growth of morphine, buprenorphine, and other drugs market. As per recent studies, chronic pain impacts more than 1.5 billion people globally. Opioid medications remain the standard treatment for moderate to severe chronic pain. However, increased awareness regarding opioid addiction risks may somewhat hamper market growth during the forecast period.

Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/4637

Top Companies Covered In This Report: Purdue Pharma, Sun Pharmaceuticals, Pfizer Inc., West Ward Pharmaceuticals, Teva Pharmaceuticals, Piramal Pharmaceuticals, Hikama Pharmaceuticals, Indivior PLC, Oreoxo AB, Camurus AB, and Novartis

Market Segmentation:

By Drug: Morphine, Buprenorphine, Noscapin, Thebaine, Etrophine

By Application: Pain Management, Opioid Addiction Treatment, Others

By Route Of Administration: Injectable, Oral, Transdermal

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Others

Geographically, the detailed analysis of consumption, revenue, Morphine, Buprenorphine, and Other Drugs Market share, growth rate, etc. of the following regions:

» North America (United States, Canada, and Mexico)
» Europe (Germany, France, UK, Russia, Italy)
» Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
» Latin America (Brazil, Argentina, Colombia)
» Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Increased prevalence of chronic pain is a key market driver

The prevalence of chronic pain conditions such as arthritis, cancer pain, back pain, and neurological disorders has significantly increased over the years. Chronic pain affects around 20% to 30% of the global adult population and is a leading cause of disability worldwide. The rising geriatric population prone to age-related chronic pain issues also supports market growth. Strong clinical evidence demonstrating the effectiveness of morphine, buprenorphine and other opioid drugs in managing moderate to severe types of chronic pain has boosted their demand over other treatment options.

Growing cancer incidence augments the demand for palliative care drugs

Cancer incidence has been steadily rising globally due to aging populations and changing lifestyle habits. According to WHO, around 19 million new cancer cases and 10 million cancer deaths occurred worldwide in 2020. Majority of advanced and terminal stage cancer patients suffer from severe pain requiring palliative therapy. Morphine remains the mainstay drug for managing cancer pain in this end-use segment. Meanwhile, opioid drugs like buprenorphine are also increasingly prescribed for cancer pain that is not adequately controlled by other medications. This growing cancer burden significantly contributes to the rising uptake of opioid analgesics in palliative care.

Direct Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4637

Increased regulations on opioid prescriptions restrain market potential

Over the past few years, there has been a strong regulatory push towards controlling the opioid epidemic impacting several countries. Tighter controls have been imposed on opioid prescribing practices and suspicious orders are closely monitored by drug enforcement agencies. Strict guidelines and policies limiting initial prescription quantities and duration have been formulated to curb misuse and abuse. However, such regulations aimed at preventing diversion have unintentionally restricted access to these medications for legitimate chronic pain patients as well. This regulatory scenario poses a challenge to the sustainable growth of the morphine, buprenorphine and other opioid drugs market.

Adoption of abuse-deterrent formulations presents commercial opportunities

In response to the rising tide of opioid misuse, pharmaceutical companies are incentivized to develop abuse-deterrent formulations of these drugs that are intended to make non-oral routes of administration difficult or ineffective. The FDA has prioritized the development and approval of such formulations to help address the public health crisis. Drugs with physical and chemical barriers to tampering, extraction of active ingredients, or respiratory depression are granted additional regulatory exclusivities and patent protections. This provides major first-mover advantages and blocks generic competition for extended periods. The commercial success of abuse-deterrent opioids in addressing unmet needs also encourages sustained R&D investments.

Increased uptake of long-acting formulations is a key market trend

Over time, market demand has shifted towards longer-acting formulations of morphine, buprenorphine and other opioids that offer convenience of once-daily or twice-daily dosing over short-acting versions. Extended-release tablets, capsules, transdermal patches allow stable and consistent drug levels in the bloodstream, thereby providing around-the-clock pain relief. They also help improve medication adherence compared to drugs requiring multiple daily doses. Major pharmaceutical innovators have expanded their product portfolios with the launch of various long-acting and controlled-release opioid products tailored for both acute and chronic pain treatment. This shifting preference will continue driving the morphine, buprenorphine and other drugs market over the forecast period.

Reason to Buy Our Market Research Report:

- Enhance your decision-making capability in a more rapid and time-sensitive manner.
- Identify key growth and investment opportunities in the Thrombolytic Therapy market.
- Facilitate decision-making based on strong historic and forecast data for the Thrombolytic Therapy market.
- Position yourself to gain the maximum advantage of the industry's growth potential.
- Identify key partners and business development avenues.
- Understand and respond to your competitors' business structure, strategy, and prospects

𝐅𝐀𝐐'𝐬

Q.1 What are the main factors influencing the Morphine, Buprenorphine, and Other Drugs market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market's opportunities, risks, and general structure?
Q.4 Which of the top Morphine, Buprenorphine, and Other Drugs Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Morphine, Buprenorphine, and Other Drugs market's distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area's assessment of agreements, income, and value implicate?

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/4637

Contact Us:

Mr. Shah
Coherent Market Insights Pvt. Ltd,
📞Phone: U.S.: +1-206-701-6702
📞U.K.: +44-020-8133-4027
📞JAPAN: +81-50-5539-1737
📞INDIA: +91-848-285-0837
✉ Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.